London is set to become a testing ground for AI-driven medical technologies following the launch of a new regulatory sandbox designed to help innovation move more quickly and safely into real-world NHS use.
The initiative, announced this week, is being led by the Medicines and Healthcare products Regulatory Agency (MHRA) in partnership with NHS England and London’s Health Innovation Network (HIN). The sandbox will provide a controlled testing environment where selected companies can deploy AI-enabled medical devices with clinicians across London, while working closely with regulators to generate robust real-world evidence.
The program is at the heart of the newly announced London Life Sciences Strategy, which aims to make the capital the world’s most attractive city for life sciences innovation, while ensuring innovation leads to better and more equitable healthcare outcomes for patients.
Despite London’s strengths, including nearly 10 million patients, three of the world’s top 15 research universities, and more than 2,700 life sciences companies, promising medical technologies have historically struggled to advance beyond small-scale, localized pilots. Fragmented procurement, duplicate evaluations, and regulatory uncertainty often delay large-scale implementation.
“What’s missing is the coordination to bring all of this together,” London’s medical director Chris Strether said in a press release. “For the first time, we have a coherent, system-wide plan to take innovations from promising experimental stages to widespread adoption, ensuring that the benefits reach all Londoners, not just those in the most advantaged communities.”
Continue reading below…
A controlled environment for AI innovation
The MHRA’s regulatory sandbox will initially focus on AI-driven devices and diagnostics, building on the authority’s existing AI Airlock program and drawing on lessons from other government initiatives such as the Financial Conduct Authority’s regulatory sandbox.
Up to 10 AI medical device manufacturers will be selected for the first phase and will work with NHS providers across London to bring the technology into real-world clinical settings, with oversight from the MHRA. By enabling results-based deployment, the sandbox aims to generate high-quality evidence of safety and efficacy while providing innovators with a clearer and more predictable route to adoption.
“This work shows that regulation can be an enabler of innovation, rather than a barrier,” MHRA CEO Lawrence Tallon said in a press release. “We need to work faster to keep up with developments in AI to ensure that patients can safely benefit from cutting-edge technology as it becomes available.”
The sandbox also responds to increasing pressure on the NHS. Adverse drug reactions alone send around 250,000 people to hospital each year and cost more than £2 billion (US$2.7 billion) a year. Meanwhile, approximately 90% of drugs fail during development. This is often because early testing methods have difficulty predicting real-world safety risks. Regulators hope that AI tools tested through the sandbox can improve safety assessments, identify side effects early and reduce costly late-stage failures.
Transforming data, finance and procurement
The Regulatory Sandbox is one of six London-wide programs outlined in the Life Sciences Strategy, which aim to work together to transform the capital into a coordinated health innovation zone.
Other initiatives include a new London Health Innovation Fund to improve access to non-dilutive funding and align up to £900m (US$1.2bn) of NHS working capital for transformational projects. Procurement and contracting reforms are also planned, enabling innovative solutions to be purchased across London and long-term strategic partnerships with suppliers.
To reduce duplication in decision-making, London will introduce an “innovator passport” through a central digital platform known as MedTech Compass. These passports allow companies to submit a single standardized evidence file covering regulatory status, quality systems, data protection, cybersecurity and clinical evidence, which can be reviewed by multiple NHS purchasers.
The strategy will also expand secure access to London’s vast healthcare data assets. Through OneLondon, approved researchers and innovators will be able to use anonymised data from nine million Londoners across primary care, hospitals, mental health and social care to support research in areas such as cardiovascular disease and health disparities.
Focus on results, not technology
Importantly, this strategy emphasizes that innovation is not an end in itself. Health inequalities across London have worsened since the coronavirus pandemic, and the new program has a clear focus on outcomes such as earlier detection of cancer, better management of long-term conditions and reducing care disparities.
Continue reading below…
“Londoners deserve the best that modern medicine has to offer,” said Caroline Clarke, director of NHS London, in a press release. “This program aims to enable London’s NHS to implement the latest technology quickly, safely and in a way that truly improves patient care.”
For industry, sandboxes provide a clearer and more predictable regulatory route for AI technologies designed to support drug discovery, pharmacovigilance, and clinical development. By collaborating with regulators from the beginning, companies can refine their tools in line with regulators’ expectations and potentially reduce post-development delays.
With expressions of interest opening next month, the partners behind the program are positioning London not only as a testbed for AI in healthcare delivery, but also as a platform to generate the real-world evidence needed to support safer and more efficient drug discovery and development.
